{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:59:06Z","timestamp":1790222346240,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T00:00:00Z","timestamp":1656201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T00:00:00Z","timestamp":1656201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination plays a crucial role as pivotal strategy to curb the coronavirus disease-19 (COVID-19) pandemic. The present study described the clinical status of patients affected by idiopathic inflammatory myopathies (IIM) after COVID-19 vaccination to assess the number of relapses. We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo. They underwent a telephone survey. A total of 119 IIM patients (median, IQR 58 (47\u201366) years; 32males; 50 dermatomyositis, 39 polymyositis and 30 anti-synthetase syndrome) were consecutively enrolled. Except four patients who refused the vaccination, 94 (81.7%) received Comirnaty, 16 (13.9%) Spikevax, 5 (4.4%) Vaxzevria. Seven (6.1%) patients had flare after vaccination. One of them had life-threatening systemic involvement and died two months after second dose of COVID-19 vaccination. From logistic regression analysis, Chi<jats:sup>2<\/jats:sup>-log ratio\u2009=\u20090.045,the variable that most influences the development of flare was the number of organs involved (<jats:italic>p<\/jats:italic>\u2009=\u20090.047). Sixty-eight patients received the third dose of COVID-19 vaccination: 51(75%) Comirnaty and 17 (25%) Moderna. No patients had flares after third dose. Our study represents the largest cohort of IIM patients in which the incidence of recurrence after anti-SARS-CoV-2 vaccine was assessed. In line with real-life data from other diseases, we found a clinical non-statistically significant risk of relapse in our patients, which occurred seldom, usually mild and in patients with a more severe and aggressive course of disease.<\/jats:p>","DOI":"10.1007\/s11739-022-03028-3","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T17:02:32Z","timestamp":1656262952000},"page":"1921-1928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study"],"prefix":"10.1007","volume":"17","author":[{"given":"Edoardo","family":"Conticini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-5722","authenticated-orcid":false,"given":"Miriana","family":"d\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Grazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Sabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Colafrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Priori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,26]]},"reference":[{"key":"3028_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"3028_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"3028_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"3028_CR4","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/IDR.S315727","volume":"14","author":"MT Mascellino","year":"2021","unstructured":"Mascellino MT, Di Timoteo F, De Angelis M, Oliva A (2021) Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist 14:3459\u20133476. https:\/\/doi.org\/10.2147\/IDR.S315727","journal-title":"Infect Drug Resist"},{"key":"3028_CR5","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10067-019-04512-6","volume":"38","author":"B Pinto","year":"2019","unstructured":"Pinto B, Janardana R, Nadig R et al (2019) Comparison of the 2017 EULAR\/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies. Clin Rheumatol 38:1931\u20131934. https:\/\/doi.org\/10.1007\/s10067-019-04512-6","journal-title":"Clin Rheumatol"},{"key":"3028_CR6","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"3028_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","volume":"14","author":"LG Rider","year":"2018","unstructured":"Rider LG, Aggarwal R, Machado PM et al (2018) Update on outcome assessment in myositis. Nat Rev Rheumatol 14:303\u2013318. https:\/\/doi.org\/10.1038\/nrrheum.2018.33","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 11","key":"3028_CR8","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider LG, Werth VP, Huber AM et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 63(Suppl 11):S118-157. https:\/\/doi.org\/10.1002\/acr.20532","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3028_CR9","unstructured":"COVID-19 Studies from the World Health Organization Database-ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/who_table. Accessed 7 Feb 2022"},{"key":"3028_CR10","unstructured":"EMA (2022) Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant. In: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/news\/preliminary-data-indicate-covid-19-vaccines-remain-effective-against-severe-disease-hospitalisation. Accessed 7 Feb 2022"},{"key":"3028_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","volume":"114","author":"C Zheng","year":"2022","unstructured":"Zheng C, Shao W, Chen X et al (2022) Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 114:252\u2013260. https:\/\/doi.org\/10.1016\/j.ijid.2021.11.009","journal-title":"Int J Infect Dis"},{"key":"3028_CR12","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e3","author":"MG Thompson","year":"2022","unstructured":"Thompson MG (2022) Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance\u2014VISION network, 10 states, August 2021\u2013January 2022. MMWR Morb Mortal Wkly Rep. https:\/\/doi.org\/10.15585\/mmwr.mm7104e3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3028_CR13","unstructured":"EULAR | EULAR Sars Cov 2 vaccination rmd patients. https:\/\/www.eular.org\/eular_sars_cov_2_vaccination_rmd_patients.cfm. Accessed 7 Feb 2022"},{"key":"3028_CR14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","volume":"80","author":"UM Geisen","year":"2021","unstructured":"Geisen UM, Berner DK, Tran F et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80:1306\u20131311. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220272","journal-title":"Ann Rheum Dis"},{"key":"3028_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00296-021-05046-4","volume":"42","author":"P Sen","year":"2022","unstructured":"Sen P, Gupta L, Lilleker JB et al (2022) COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatol Int 42:23\u201329. https:\/\/doi.org\/10.1007\/s00296-021-05046-4","journal-title":"Rheumatol Int"},{"key":"3028_CR16","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.1002\/jmv.27192","volume":"93","author":"E Conticini","year":"2021","unstructured":"Conticini E, d\u2019Alessandro M, Bergantini L et al (2021) Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report. J Med Virol 93:6439\u20136441. https:\/\/doi.org\/10.1002\/jmv.27192","journal-title":"J Med Virol"},{"key":"3028_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221587","author":"F Ursini","year":"2021","unstructured":"Ursini F, Ruscitti P, Raimondo V et al (2021) Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221587","journal-title":"Ann Rheum Dis"},{"key":"3028_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105334","volume":"89","author":"S Ottaviani","year":"2021","unstructured":"Ottaviani S, Juge P-A, Forien M et al (2021) Polymyalgia rheumatica following COVID-19 vaccination: a case-series of ten patients. Jt Bone Spine 89:105334. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105334","journal-title":"Jt Bone Spine"},{"key":"3028_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/jdv.17744","volume":"36","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Boms S, Susok L et al (2022) Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol 36:172\u2013180. https:\/\/doi.org\/10.1111\/jdv.17744","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3028_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/cup.14104","volume":"49","author":"V Larson","year":"2022","unstructured":"Larson V, Seidenberg R, Caplan A et al (2022) Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol 49:34\u201341. https:\/\/doi.org\/10.1111\/cup.14104","journal-title":"J Cutan Pathol"},{"key":"3028_CR21","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/S2665-9913(21)00309-X","volume":"3","author":"G Cavalli","year":"2021","unstructured":"Cavalli G, Colafrancesco S, De Luca G et al (2021) Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol 3:e743\u2013e744. https:\/\/doi.org\/10.1016\/S2665-9913(21)00309-X","journal-title":"Lancet Rheumatol"},{"key":"3028_CR22","doi-asserted-by":"publisher","first-page":"5718","DOI":"10.1002\/jmv.27175","volume":"93","author":"M Capassoni","year":"2021","unstructured":"Capassoni M, Ketabchi S, Cassisa A et al (2021) AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report. J Med Virol 93:5718\u20135720. https:\/\/doi.org\/10.1002\/jmv.27175","journal-title":"J Med Virol"},{"key":"3028_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/qjmed\/hcab043","volume":"114","author":"DJ Theodorou","year":"2021","unstructured":"Theodorou DJ, Theodorou SJ, Axiotis A et al (2021) COVID-19 vaccine-related myositis. QJM 114:424\u2013425. https:\/\/doi.org\/10.1093\/qjmed\/hcab043","journal-title":"QJM"},{"key":"3028_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/ene.15147","volume":"29","author":"LD Kaulen","year":"2022","unstructured":"Kaulen LD, Doubrovinskaia S, Mooshage C et al (2022) Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Eur J Neurol 29:555\u2013563. https:\/\/doi.org\/10.1111\/ene.15147","journal-title":"Eur J Neurol"},{"key":"3028_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3949\/ccjm.88a.21038","volume":"88","author":"S Ramalingam","year":"2021","unstructured":"Ramalingam S, Arora H, Lewis S et al (2021) COVID-19 vaccine-induced cellulitis and myositis. Cleve Clin J Med 88:648\u2013650. https:\/\/doi.org\/10.3949\/ccjm.88a.21038","journal-title":"Cleve Clin J Med"},{"key":"3028_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13256-022-03266-1","volume":"16","author":"K Vutipongsatorn","year":"2022","unstructured":"Vutipongsatorn K, Isaacs A, Farah Z (2022) Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports. J Med Case Rep 16:57. https:\/\/doi.org\/10.1186\/s13256-022-03266-1","journal-title":"J Med Case Rep"},{"key":"3028_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.41924","volume":"74","author":"CM Connolly","year":"2022","unstructured":"Connolly CM, Ruddy JA, Boyarsky BJ et al (2022) Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol 74:28\u201332. https:\/\/doi.org\/10.1002\/art.41924","journal-title":"Arthritis Rheumatol"},{"key":"3028_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102743","volume":"125","author":"AG Tzioufas","year":"2021","unstructured":"Tzioufas AG, Bakasis A-D, Goules AV et al (2021) A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun 125:102743. https:\/\/doi.org\/10.1016\/j.jaut.2021.102743","journal-title":"J Autoimmun"},{"key":"3028_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221736","author":"Y Fan","year":"2021","unstructured":"Fan Y, Geng Y, Wang Y et al (2021) Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221736","journal-title":"Ann Rheum Dis"},{"key":"3028_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001847","volume":"8","author":"V Venerito","year":"2022","unstructured":"Venerito V, Stefanizzi P, Fornaro M et al (2022) Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. RMD Open 8:e001847. https:\/\/doi.org\/10.1136\/rmdopen-2021-001847","journal-title":"RMD Open"},{"key":"3028_CR31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","volume":"41","author":"LE Bartels","year":"2021","unstructured":"Bartels LE, Ammitzb\u00f8ll C, Andersen JB et al (2021) Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 41:1925\u20131931. https:\/\/doi.org\/10.1007\/s00296-021-04972-7","journal-title":"Rheumatol Int"},{"key":"3028_CR32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210863","author":"M Fornaro","year":"2022","unstructured":"Fornaro M, Venerito V, Iannone F, Cacciapaglia F (2022) Safety Profile and low risk of disease relapse after BNT162b2 mRNA SARS-CoV-2 vaccination in patients with rare rheumatic diseases. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.210863","journal-title":"J Rheumatol"},{"key":"3028_CR33","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330\u20131338. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220647","journal-title":"Ann Rheum Dis"},{"key":"3028_CR34","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00296-021-04917-0","volume":"41","author":"S Cherian","year":"2021","unstructured":"Cherian S, Paul A, Ahmed S et al (2021) Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol Int 41:1441\u20131445. https:\/\/doi.org\/10.1007\/s00296-021-04917-0","journal-title":"Rheumatol Int"},{"key":"3028_CR35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/vaccines9070730","volume":"9","author":"C Rotondo","year":"2021","unstructured":"Rotondo C, Cantatore FP, Fornaro M et al (2021) Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a two-centers study. Vaccines (Basel) 9:730. https:\/\/doi.org\/10.3390\/vaccines9070730","journal-title":"Vaccines (Basel)"},{"key":"3028_CR36","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/jpm11121283","volume":"11","author":"L Pinte","year":"2021","unstructured":"Pinte L, Negoi F, Ionescu GD et al (2021) COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases. J Pers Med 11:1283. https:\/\/doi.org\/10.3390\/jpm11121283","journal-title":"J Pers Med"},{"key":"3028_CR37","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","volume":"85","author":"S Wack","year":"2021","unstructured":"Wack S, Patton T, Ferris LK (2021) COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol 85:1274\u20131284. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.054","journal-title":"J Am Acad Dermatol"},{"key":"3028_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab773","author":"SK Shinjo","year":"2021","unstructured":"Shinjo SK, de Souza FHC, Borges IBP et al (2021) Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab773","journal-title":"Rheumatology (Oxford)"},{"key":"3028_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927","volume":"21","author":"A Jena","year":"2022","unstructured":"Jena A, Mishra S, Deepak P et al (2022) Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev 21:102927. https:\/\/doi.org\/10.1016\/j.autrev.2021.102927","journal-title":"Autoimmun Rev"},{"key":"3028_CR40","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","volume":"125","author":"C Ferri","year":"2021","unstructured":"Ferri C, Ursini F, Gragnani L et al (2021) Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups. J Autoimmun 125:102744. https:\/\/doi.org\/10.1016\/j.jaut.2021.102744","journal-title":"J Autoimmun"},{"key":"3028_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa863","author":"M Fung","year":"2020","unstructured":"Fung M, Babik JM (2020) COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa863","journal-title":"Clin Infect Dis"},{"key":"3028_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13075-021-02674-w","volume":"24","author":"FR Spinelli","year":"2022","unstructured":"Spinelli FR, Favalli EG, Garufi C et al (2022) Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther 24:21. https:\/\/doi.org\/10.1186\/s13075-021-02674-w","journal-title":"Arthritis Res Ther"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-03028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-022-03028-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-03028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T13:42:19Z","timestamp":1664458939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-022-03028-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,26]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3028"],"URL":"https:\/\/doi.org\/10.1007\/s11739-022-03028-3","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,26]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee (C.E.A.V.S.E. OSS_REOS n\u00b0 12908; Markerlung 17431; Rhelabus 22271).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}